PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT

Status Not yet recruiting

Clinical Trial Summary

The study consists of a 25 ml blood sample collection: - Before the start of treatment - Approximately 2 months after the start of induction chemotherapy - At the end of induction chemotherapy - Prior to local treatment (radiotherapy, surgery) - At the time of tumor progression Collection of tumor material: - During the initial diagnostic biopsy - On the operating room in case of surgery - At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05802485
Study type	Interventional
Source	Institut Paoli-Calmettes
Contact	Dominique GENRE, MD
Phone	+33491223778
Email	drci.up@ipc.unicancer.fr
Status	Not yet recruiting
Phase	N/A
Start date	April 30, 2023
Completion date	February 1, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02128100` - Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT05047991` - Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma	Phase 2
Completed	`NCT03590275` - Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX
Recruiting	`NCT05265663` - Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients	N/A
Recruiting	`NCT05642962` - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1/Phase 2
Recruiting	`NCT06160323` - Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer	N/A
Active, not recruiting	`NCT04156087` - Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer	Phase 2
Active, not recruiting	`NCT03941093` - Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer	Phase 3
Recruiting	`NCT03165591` - Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer	Phase 1/Phase 2
Recruiting	`NCT05549414` - Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System	N/A
Not yet recruiting	`NCT06375967` - EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)	N/A
Withdrawn	`NCT04852367` - PanDox: Targeted Doxorubicin in Pancreatic Tumours	Phase 1
Recruiting	`NCT03977233` - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer	Phase 2
Recruiting	`NCT03964064` - I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer	N/A
Not yet recruiting	`NCT06361030` - Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT05424159` - Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer	N/A
Terminated	`NCT01887041` - Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer	Phase 4
Active, not recruiting	`NCT03984214` - Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer	Phase 3
Recruiting	`NCT05262452` - Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer	N/A
Recruiting	`NCT04986930` - mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma	Phase 2